Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
Kala Pharmaceuticals, Inc. (KALA)
Last kala pharmaceuticals, inc. earnings: 2/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.kalarx.com
Company Research
Source: GlobeNewswire
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company at the forefront of artificial intelligence and cell and gene therapy innovation, today announced the engagement of Dr. Saeid Babaei, PhD, MBA, as Senior Scientific Advisor. Dr. Babaei’s engagement will focus on advising on the evaluation of Kala’s clinical and molecular assets, including the proprietary MSC Secretome platform, through the potential application of AI-enabled analytics, digital health tools, and secure data integration approaches. His mandate includes advising on clinical development considerations, assessing hypotheses related to potential responder subgroups, and contributing scientific input to the development of a responsible, regulatory-conscious analytical framework for enterprise-scale biotech applications. Strategic Context: Unlocking Value Through Amended Indications This collaboration marks a pivotal step in Kala Bio's strategy to maximize
Show less
Read more
Impact Snapshot
Event Time:
KALA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALA alerts
High impacting Kala Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALA
News
- KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now LiveGlobeNewswire
- Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug CandidateGlobeNewswire
- Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution AcceleratesGlobeNewswire
- KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “ReseargencGlobeNewswire
- KALA BIO Settles Approximately $10.6 million of DebtGlobeNewswire
KALA
Sec Filings
- 3/31/26 - Form NT
- 3/17/26 - Form D
- 3/17/26 - Form 144
- KALA's page on the SEC website